Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

FDA schedules Type A meeting for Ascelia’s Orviglance NDA

Ascelia Pharma (STO: ACE) has announced that the U.S. Food and Drug Administration (FDA) has scheduled a Type A meeting for September 9, 2026 to discuss the Complete Response Letter (CRL) issued on July 2, 2026...

August 17, 2026

Developments

OmniAb and Eli Lilly collaborate on new ion channel program

OmniAb (NASDAQ: OABI) has announced a global collaboration and license agreement with Eli Lilly and Company (NYSE: LLY) for a new ion channel program, leveraging OmniAb’s technology platform and expertise in ion channel...

August 17, 2026

Developments

Profound’s new real-time interventional MRI software to pave the way for full ‘TULSA days’

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced the introduction of its latest Treatment Delivery Console (TDC) software being deployed across Profound’s TULSA-PRO-installed base. According to Profound, the TDC...

August 17, 2026

Developments

Profound launches ‘Let’s Huddle’, a global community supporting men through prostate care

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced the launch of Let’s Huddle, a global patient community designed to empower men and their families with education, connection, and support throughout every...

August 14, 2026

Developments

Intermountain Health becomes first to bring Perimeter’s Claire to the operating room

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that Intermountain Health, in the Mountain West region, has become the first health system in the U.S. to commercially deploy Perimeter’s...

August 13, 2026

Developments

USPTO grants Alterity new composition of matter patent

Alterity Therapeutics (ASX: ATH; NASDAQ: ATHE) has announced that the United States Patent and Trademark Office (USPTO) has granted a new composition of matter patent for the company’s lead clinical asset, ATH434, an...

August 12, 2026

Developments

Valion announces U.S. government-funded Entolimod studies targeting lethal radiation-induced GI injury

Valion Bio (NASDAQ: VBIO) has announced that the Armed Forces Radiobiology Research Institute (AFRRI), under its contract with the National Institute of Allergy and Infectious Diseases, is conducting a U.S. Department...

August 12, 2026

Developments

Clearmind announces positive results for intranasal MEAI

Clearmind Medical (NASDAQ: CMND; FSE: CWY0) has announced positive permeation study results from its ongoing intranasal MEAI development program. According to Clearmind, early-stage studies of its intranasal MEAI...

August 11, 2026

Developments

SL Science co-authors Biomedicines article on γδ T Cell Therapy in Glioblastoma

SL Science Holding (NASDAQ: SLBT) has announced the publication of a peer-reviewed article in Biomedicines co-authored by SL Science leadership and clinical researchers from Taipei Medical University outlining a...

August 11, 2026

Developments

Vivos expands Greenway partnership

Vivos Therapeutics (NASDAQ: VVOS) has announced an expanded strategic engagement with closely held Greenway Health, a leading healthcare technology company, to deploy Greenway’s new AI-by-design Novare platform across...

August 11, 2026

Developments

Longeveron advances to final phase of XPRIZE Healthspan competition

Longeveron (NASDAQ: LGVN) announced that it has been selected from more than 600 worldwide applicants to advance to the final phase of the XPRISE Healthspan competition as a Milestone 2 Awardee team. The $1,000,000...

August 11, 2026

Developments

Silence reveals positive topline results from trial of divesiran in PV

Silence Therapeutics (NASDAQ: SLN) has announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera (PV). According...

August 10, 2026

Developments

USPTO grants Urteste patent for pancreatic cancer test

Urteste (WSE: URT) has announced that the United States Patent and Trademark Office (USPTO) granted a patent for Panuri, a non-invasive test for detecting pancreatic cancer. According to Urteste, the Panuri test is also...

August 6, 2026

Developments

Rise uplists to OTCQB; achieves DTC eligibility

Rise Nano Optics (CSE: EYE) (OTCQB: RNOLF) has announced that its common shares have been approved to commence trading on the OTCQB Venture Market and are also now DTC eligible, enhancing accessibility and efficiency of...

August 4, 2026

Developments

First site in Indiana offers Aclarion’s Nociscan for lower back pain

Aclarion (NASDAQ: ACON, ACONW) has announced that its Nociscan platform is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, marking the first site in Indiana to offer the technology...

August 4, 2026

Developments

Elite launches generic Requip XL for Parkinson’s

Elite Pharmaceuticals (OTCQB: ELTP) has launched a generic version of Requip XL (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets, for the treatment of Parkinson’s...

August 4, 2026

Developments

Lucid starts Envoy Medical at buy; PT $2

Lucid Capital Markets initiated coverage of Envoy Medical (NASDAQ:COCH) with a “buy” rating and price target of $2.00. The stock closed at $0.66 on July 24. Envoy designs, manufactures, and is working to commercialize...

July 27, 2026

Developments

Incisionless TULSA Procedure for prostate cancer demonstrated statistically significant superior penile length preservation compared to Robotic Radical Prostatectomy at 1 month

The title of Profound Medical’s (NASDAQ:PROF; TSX:PRN) press release today, “Robotic Radical Prostatectomy Comes Up ‘Short’ in CAPTAIN Trial,” playfully set the tone for its reporting of a sensitive subject: penile...

July 24, 2026

Developments

Ukraine MoH Accepts Valion Bio’s Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

Valion Bio (NASDAQ: VBIO) has announced that the regulatory dossier for its lead candidate, Entolimod for acute radiation syndrome (ARS), has been accepted by Ukraine’s Ministry of Health (MoH) for formal review...

July 22, 2026

Developments

Sheba Medical Center to self-sponsor a trial evaluating Valion Bio’s Entolimod in reducing radiation-induced neutropenia and protecting healthy tissue during cancer radiation therapy

Valion Bio (NASDAQ: VBIO) has announced a major clinical development milestone with the finalization of a clinical trial protocol at Sheba Medical Center, one of the world’s leading hospitals, to evaluate...

July 20, 2026

Developments

Casp-Aid appoints Mika Guerard as VP, Head of Drug Development

Closely held Casp-Aid has appointed Mika (Kimiaka C.) Guerard, PhD, MBA, as VP, Head of Drug Development as it makes final preparations to launch a Phase IIb clinical trial evaluating its lead small molecule, CIM765, in...

July 20, 2026

Developments

LIR and OH sign agreement to advance roadmap for transdermal obesity pipeline

LIR Life Sciences (CSE: SKNY; OTCPK: BBCMF) has announced that it has entered into a services agreement with closely held Oxygen Handel GmbH (OH), a specialized preclinical and regulatory development organization, to...

July 17, 2026

Subscribe